In the RESTORE extension study, 240 patients suffering from DME received individualised treatment with Lucentis. Results demonstrated that to maintain mean visual acuity gained in the core study, an average of 3.7 injections and 2.7 injections were required in the second and third years, respectively. It was noted that in the core RESTORE study, patients showed vision gains with an average of seven injections for a one-year period.
In a separate study, 316 wet AMD patients received individualised treatment with Lucentis, as needed, according to a disease-activity-guided monitoring and treatment algorithm. At the end of three years, vision gains similar to pivotal phase III trials MARINA and ANCHOR were observed. Results showed that an average of 16 injections was required during three years, which was less than the regimen used in pivotal phase III studies.
Lucentis is currently approved for wet AMD, visual impairment due to DME and visual impairment due to macular edema following retinal vein occlusion.
